Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study NEW BRUNSWICK, N.J. , /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today ...
Longer-term data reflecting nearly 4 years of follow-up show a further reduction in the risk of death from 14% to 37% for those initially treated with Libtayo, despite an 88% crossover from the ...
Friendly You can feel well while a stool PCR still detects norovirus RNA. Your symptoms, job, household contacts, and local ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results